109 related articles for article (PubMed ID: 9355880)
1. Monitoring tissue repair and fibrosis from a distance.
Weber KT
Circulation; 1997 Oct; 96(8):2488-92. PubMed ID: 9355880
[No Abstract] [Full Text] [Related]
2. Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer.
Ylisirniö S; Sassi ML; Risteli J; Turpeenniemi-Hujanen T; Jukkola A
Anticancer Res; 1999; 19(6C):5577-81. PubMed ID: 10697621
[TBL] [Abstract][Full Text] [Related]
3. Collagen type-I degradation is related to arterial stiffness in hypertensive and normotensive subjects.
McNulty M; Mahmud A; Spiers P; Feely J
J Hum Hypertens; 2006 Nov; 20(11):867-73. PubMed ID: 16598292
[TBL] [Abstract][Full Text] [Related]
4. Collagen: scaffold for repair or execution.
Jensen LT; Høst NB
Cardiovasc Res; 1997 Mar; 33(3):535-9. PubMed ID: 9093523
[No Abstract] [Full Text] [Related]
5. [Collagen synthesis and heart failure].
Jiménez-Navarro MF; Gómez-Doblas JJ; Cabrera-Bueno F; Cruz-Ocaña E; Rodríguez-Bailón I; Ruiz-Galdón M; Morell M; Molero E; de Teresa-Galván E
Rev Esp Cardiol; 2005 Aug; 58(8):975-8. PubMed ID: 16053832
[TBL] [Abstract][Full Text] [Related]
6. Type I and III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer.
Santala M; Simojoki M; Risteli J; Risteli L; Kauppila A
Clin Cancer Res; 1999 Dec; 5(12):4091-6. PubMed ID: 10632345
[TBL] [Abstract][Full Text] [Related]
7. Preoperative high type I collagen degradation marker ICTP reflects advanced breast cancer.
Keskikuru R; Kataja V; Kosma VM; Eskelinen M; Uusitupa M; Johansson R; Risteli L; Risteli J; Jukkola A
Anticancer Res; 1999; 19(5C):4481-4. PubMed ID: 10650796
[TBL] [Abstract][Full Text] [Related]
8. [Serum levels of carboxyterminal propeptide of type I procollagen (PICP), cross-linked carboxyterminal telopeptide region of type I collagen (ICTP) and carboxyterminal parathyroid hormone-related protein (C-PTHrP) in hematological malignancies with bone lesions and hypercalcemia].
Tanaka K; Shiraishi K; Sakamoto A; Jojima H; Masuchi K; Okubo Y; Tanaka M; Fuzimatsu Y; Fukahori S; Osabe S; Imamura Y; Honda J; Oizumi K
Rinsho Ketsueki; 1998 Apr; 39(4):273-80. PubMed ID: 9597894
[TBL] [Abstract][Full Text] [Related]
9. Serum markers of bone metabolism in dogs.
Allen MJ; Hoffmann WE; Richardson DC; Breur GJ
Am J Vet Res; 1998 Mar; 59(3):250-4. PubMed ID: 9522938
[TBL] [Abstract][Full Text] [Related]
10. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction.
Hayashi M; Tsutamoto T; Wada A; Tsutsui T; Ishii C; Ohno K; Fujii M; Taniguchi A; Hamatani T; Nozato Y; Kataoka K; Morigami N; Ohnishi M; Kinoshita M; Horie M
Circulation; 2003 May; 107(20):2559-65. PubMed ID: 12732605
[TBL] [Abstract][Full Text] [Related]
11. Biochemical assessment of myocardial fibrosis in hypertensive heart disease.
López B; González A; Varo N; Laviades C; Querejeta R; Díez J
Hypertension; 2001 Nov; 38(5):1222-6. PubMed ID: 11711527
[TBL] [Abstract][Full Text] [Related]
12. [Measurements and clinical usefulness of carboxyterminal propeptide of type I collagen and cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer].
Igawa T; Sakai H; Kanetake H; Saito Y
Hinyokika Kiyo; 1999 Apr; 45(4):235-9. PubMed ID: 10363141
[TBL] [Abstract][Full Text] [Related]
13. Type I collagen metabolites as tumor markers in patients with lung carcinoma.
Kobayashi T; Gabazza EC; Taguchi O; Risteli J; Risteli L; Kobayashi H; Yasui H; Yuda H; Sakai T; Kaneda M; Adachi Y
Cancer; 1999 May; 85(9):1951-7. PubMed ID: 10223235
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6 and tumor necrosis factor alpha in relation to myocardial infarct size and collagen formation.
Puhakka M; Magga J; Hietakorpi S; Penttilä I; Uusimaa P; Risteli J; Peuhkurinen K
J Card Fail; 2003 Aug; 9(4):325-32. PubMed ID: 13680554
[TBL] [Abstract][Full Text] [Related]
15. Bone marker alterations in patients with type 1 Gaucher disease.
Ciana G; Martini C; Leopaldi A; Tamaro G; Katouzian F; Ronfani L; Bembi B
Calcif Tissue Int; 2003 Mar; 72(3):185-9. PubMed ID: 12522660
[TBL] [Abstract][Full Text] [Related]
16. How is Type I procollagen synthesis regulated at the gene level during tissue fibrosis.
Cutroneo KR
J Cell Biochem; 2003 Sep; 90(1):1-5. PubMed ID: 12938150
[TBL] [Abstract][Full Text] [Related]
17. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
Noguchi M; Noda S
J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
[TBL] [Abstract][Full Text] [Related]
18. Effect on collagen metabolism of thrombolytic therapy with tissue-plasminogen activator. A randomized, placebo-controlled study.
Høst NB; Stoltenberg MB; Jensen LT; Larsen OG; Aurup P
Eur J Clin Invest; 1995 Jan; 25(1):15-8. PubMed ID: 7705381
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the relationship between dynamic pattern of nighttime levels of melatonin and chosen biochemical markers of bone metabolism in a rat model of postmenopausal osteoporosis.
Ostrowska Z; Kos-Kudla B; Swietochowska E; Marek B; Kajdaniuk D; Górski J
Neuro Endocrinol Lett; 2001 Apr; 22(2):129-36. PubMed ID: 11335889
[TBL] [Abstract][Full Text] [Related]
20. Changes in biochemical parameters of bone turnover and bone mineral density in post-pregnancy osteoporosis.
Honjo S; Mizunuma H
Am J Obstet Gynecol; 2001 Jul; 185(1):246-7. PubMed ID: 11483939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
